Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Clinical trial NCT06241807 · RECRUITING

Trial details

NCT number: NCT06241807
Sponsor: Shandong Cancer Hospital and Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IMMUNOTHERAPY Neoadjuvant Therapy Resectable Lung Non-Small Cell Carcinoma Biomarkers / Blood

Start date: 2022-12-02
Primary completion: 2024-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.